Amyloid-clearing therapy for dementia with Lewy bodies plus Alzheimer's disease

Who could benefit from this research

What this research studies

This patient-facing study investigates whether a monoclonal antibody that clears amyloid can be safely used in individuals with both DLB and AD. It is a phase 2, double-blind, placebo-controlled trial enrolling about 400 participants, with an additional 12-month observational follow-up to collect more clinical, imaging, and biomarker data. By combining AD and DLB pathology in a single trial, researchers aim to understand potential benefits or harms in this specific mixed-dementia population. If successful, the study could inform future treatment options for patients with co-occurring DLB and AD. The research is conducted at Stanford University and will involve close monitoring for adverse effects and meaningful changes in disease markers.

Why it matters

Where this research is happening

• Stanford University
  Stanford, United States Active

Researchers

• Principal investigator: Sha, Sharon J — Stanford University
• Study coordinator: Sha, Sharon J

Related research

Other NIH-funded projects on the same topics.

• Understanding how heparan sulfate affects alpha-synuclein in Lewy body dementia

  A small study in people who have dementia with Lewy bodies looks at how a brain sugar (heparan sulfate) helps a harmful protein (alpha-synuclein) spread, with the hope of slowing disease progression.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11606576

• Global picture of dementia risk and memory loss across the world

  A large international effort gathers data from many studies to understand how dementia and memory problems develop around the world, using shared information to reveal patterns and risk factors.

  NIH research University of New South Wales · Sydney, Australia · NIH-11603263

• Automated language analysis for Alzheimer’s disease and frontotemporal dementia in Latino and English speakers

  A low-cost, automated speech and language analysis tool is being developed to help identify Alzheimer’s disease or frontotemporal dementia in Latino and English-speaking people.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11553470

• Automated language analysis for Alzheimer’s and frontotemporal dementia across Latino and English-speaking groups

  A low-cost, automated language study aims to help diagnose and understand Alzheimer’s and FTD in diverse Spanish- and English-speaking communities.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11553469

• Automated language analysis to help diagnose Alzheimer’s and frontotemporal dementia in Latino and English speakers

  A low-cost, computer-based method analyzes speech and language to help identify Alzheimer’s disease or frontotemporal dementia in Latino and English-speaking people.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11553467

• Automated language analysis for Alzheimer's and frontotemporal dementia in Latino and English-speaking communities

  A low-cost, computer-based language analysis method is being developed to help identify Alzheimer’s disease and frontotemporal dementia in Latino and English-speaking people.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11553466

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.